PROTAGONIST THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.22 USD | -1.37% |
|
-8.82% | +9.99% |
Presenter SpeechAnupam Rama (Analysts)Welcome, everyone, to the 40th Annual JPMorgan Healthcar...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Companyâs clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Companyâs Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Calendar
2024-04-30
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
25.22
USD
Average target price
43
USD
Spread / Average Target
+70.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +9.99% | 1.47B | |
| -1.82% | 41.35B | |
| +41.98% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- PTGX Stock
- News Protagonist Therapeutics, Inc.
- Transcript : Protagonist Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-11-2022 02
